Max Healthcare Institute Ltd (MAXHEALTH) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management will dynamically manage institutional patient mix, de-empanelling hospitals at full capacity and empanelling new facilities to drive initial volumes.
- The Gurgaon greenfield will launch by fiscal year-end, with an expected peak EBITDA loss of INR 40-50 crores during its ramp-up period.
- The Board approved a new INR 415 crore investment for 209 brownfield beds, signaling continued aggressive capacity expansion at existing locations.
Performance Overview
- Delivered strong Q2 FY27 performance with 20% revenue growth and 18% operating EBITDA growth year-on-year.
- Maintained a steady network occupancy of 77% despite a 14% year-on-year increase in operational bed capacity.
- Successfully ramped up brownfield expansions in Mumbai, Mohali, and Saket, with the new beds at Max Smart achieving EBITDA breakeven within three months.
- International patient revenue grew significantly by 33% year-on-year, now constituting 10% of hospital healthcare revenue.
- Strategic business units, Max@Home and Max Lab, continued their robust growth trajectories, reporting year-on-year revenue growth of 37% and 24% respectively.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.